No Data
No Data
No Data
No Data
No Data
Marker Therapeutics' MT-601 Shows Promising Results
TipRanksApr 8 12:07 ET
Marker Therapeutics Advances in Immuno-Oncology
TipRanksMar 26 13:07 ET
Marker Therapeutics GAAP EPS of -$1.59, Revenue of $3.31M
Seeking AlphaMar 26 01:13 ET
Express News | Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
Moomoo 24/7Mar 25 17:56 ET
Press Release: Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response
Dow JonesMar 25 17:45 ET
Marker Therapeutics Ends Stock Sale Deal With LPC
TipRanksMar 1 08:12 ET
No Data
No Data